Ursodiol is indicated for patients with radiolucent noncalcified gallbladder stones, and for the prevention of gallstone formation in obese patients experiencing rapid weight loss.
Arthur Bedrosian, president and CEO of Lannett, said: “The approval of Ursodiol expands our product offering and adds to the significant number of product approvals Lannett has received thus far in 2008.
“We continue to build a robust, diversified pipeline and remain optimistic that our growth strategy will continue to pay dividends. Our accomplishments this year are the result of the hard work and dedication of our employees.”